Linagliptin: A thorough Characterization beyond Its Clinical Efficacy by Maria Angela Sortino et al.
REVIEW ARTICLE
published: 26 February 2013
doi: 10.3389/fendo.2013.00016
Linagliptin: a thorough characterization beyond its clinical
efficacy
Maria Angela Sortino1*,Tiziana Sinagra1 and Pier Luigi Canonico2
1 Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy
2 Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy
Edited by:
Romesh Khardori, Eastern Virginia
Medical School, USA
Reviewed by:
Undurti Narasimha Das, UND Life
Sciences, USA
Sarah Louise Gray, University of
Northern British Columbia, Canada
*Correspondence:
Maria Angela Sortino, Department of
Clinical and Molecular Biomedicine,
Section of Pharmacology and
Biochemistry, University of Catania,
Viale Andrea Doria 6, 95125 Catania,
Italy.
e-mail: msortino@unict.it
Linagliptin, one of the five dipeptidyl peptidase-4 inhibitors available, has recently entered
the market both in the US and in most European countries for treatment of type 2 diabetes
mellitus. It presents a xanthine-based structure, and is characterized by unique pharma-
cokinetics, with non-linear profile, long terminal half-life allowing prolonged exposure to
the drug. It is eliminated predominately through the intestinal tract and only minimally
into urine, so that it can be administered, without any dose adjustment, in conditions
of renal impairment. Linagliptin is effective in modifying all parameters of hyperglycemia
either in monotherapy, or as add-on therapy, together with metformin or a sulfonylurea.
It also exhibits a good tolerability profile with few side effects, absence (when used in
monotherapy), or low risk (when in combination with a sulfonylurea) of hypoglycemia.
More importantly it has a weight neutral effect. A comprehensive report of the literature
on linagliptin is provided, paying attention in particular to preclinical studies, interactions
with other drugs, safety and tolerability, and results obtained in animal models that high-
light properties of linagliptin suggestive of potential additional uses. Particularly promising
appear the data demonstrating a positive effect of linagliptin on metabolic dysfunction
and renal and/or cardiovascular damage together with more recently reported effects of
linagliptin on tissue repair and neuroprotection.
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INTRODUCTION
The devastating prevalence of type 2 diabetes mellitus (T2DM),
together with better knowledge of pathogenesis of the disease,
have prompted search for new treatment strategies. Dipeptidyl
peptidase-4 (DPP-4) inhibitors offer novel opportunities for the
management of T2DM as they are endowed with a new mechanism
of action, potentiating the physiological function of endogenous
incretin, glucagon-like peptide 1 (GLP-1). Although cleavage of
GLP-1 is recognized as the only clinically relevant enzymatic effect
of DPP-4, this enzyme recognizes as target glucose-dependent
insulinotropic polypeptide (GIP), another incretin that shares
insulinotropic activity with GLP-1, but is devoid of other prop-
erties such as reduction of glucagon release, delay of gastric emp-
tying, and suppression of appetite (Baggio and Drucker, 2007). In
addition, besides incretins, other substrates of DPP-4, not directly
involved in the control of glycemic homeostasis have been iden-
tified. These include different peptides with recognized renal and
cardiovascular effects such as Brain Natriuretic Peptide (BNP),
Neuropeptide Y (NPY), Peptide YY (PYY), and type 1 Stromal-
Derived Factor (SDF-1α; Hocher et al., 2012a). Although we are far
from identifying a direct link between inhibition of DPP-4, modi-
fied cleavage of these peptides and clinical correlates, it cannot be
excluded that changes in their metabolism account for additional
outcomes of DPP-4 inhibition that are increasingly emerging from
preclinical studies.
Drugs belonging to the class of DPP-4 inhibitors are virtually
devoid of any hypoglycemic effect and have no significant impact
on body weight. In addition, with respect to other drugs belong-
ing to the incretin family, DPP-4 inhibitors offer the undeniable
advantage of oral administration. Five DDP-4 inhibitors are avail-
able, including sitagliptin, saxagliptin, vildagliptin, and the more
recent linagliptin and alogliptin (Russell-Jones and Gough, 2012).
At present sitagliptin, linagliptin and saxagliptin are marketed
in US, sitagliptin, saxagliptin, and vildagliptin have been approved
in Europe and alogliptinis already present only in the Japanese
market and has just received approval by US Food and Drug
Administration (FDA). Linagliptin represents the most recently
approved of this class of anti-diabetic drugs both in US and
Europe.
Rather than analyzing the clinical properties of linagliptin,
when used either as monotherapy or as add-on therapy to other
anti-diabetic drugs, this review is aimed at emphasizing specific
features of this molecule from preclinical studies to pharmaco-
kinetics and interaction with other drugs. Particular attention is
given to linagliptin effect in animal models, as this may represent a
unique opportunity to know in depth features of the molecule that
can help to disclose properties not so evident from clinical studies.
CHEMISTRY
(8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-
methyl-quinazolin-2-ylmethyl)-3,7dihydropurine-2,6-dione;
linagliptin) is a DPP-4 inhibitor with a xanthine-based structure.
Its nature makes it different from other compounds of the same
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class (saxagliptin, sitagliptin, vildagliptin, with the exception of
alogliptin) that are all peptidomimetic molecules.
Linagliptin binds tightly to the core of the DPP-4 enzyme form-
ing three hydrogen bonds between the amino function on the
piperidine ring and acceptor groups on residues Glu205, Glu206,
Tyr662. A fourth hydrogen bond is formed between the C-6
carbonyl of the xanthine scaffold and the backbone amide of
residue Tyr631. Finally, aromatic stacking interactions are estab-
lished between the xanthine ring and Tyr547 as well as between
the quinazoline ring and Trp629 (Eckhardt et al., 2007).
PHARMACOLOGY: PHARMACODYNAMICS
Linagliptin inhibits DPP-4 activity in vitro with an IC50 value of
1 nM, exhibiting a potency higher than all other DDP-4 inhibitors
which yield IC50 values of 19 (sitagliptin), 24 (alogliptin), 50
(saxagliptin), and 62 (vildagliptin) nM, respectively (Thomas
et al., 2008). Maximal efficacy for DPP-4 inhibition is similar for
linagliptin and other compounds of the same class. The kinetics of
linagliptin interaction with DPP-4 reveals a slow dissociation from
the enzyme with a calculated koff rate (3× 10−5/s) that is approx-
imately 10-fold slower than the off-rate for vildagliptin (Thomas
et al., 2008).
Linagliptin exhibits a 10,000-fold higher selectivity for DPP-
4 than for other dipeptidyl peptidases such as DPP-2, DPP-8,
and DPP-9, a property that makes this molecule, together with
alogliptin, the highest selective compound vs. DPP-4. Similarly,
the selectivity of linagliptin vs. peptidases N and P, prolyl oligopep-
tidases, and proteases such as trypsin, plasmin, and thrombin is
much more than 10,000-fold. Linagliptin also inhibits fibroblast
activating protein (FAP) with an IC50 of 89 nM (about 90-fold
higher selectivity vs. DPP-4; Gao et al., 2007; Thomas et al., 2008;
Deacon, 2011). This effect appears interesting as FAP is a pro-
tease with high potentials: it is considered in fact a marker of
fibroblasts in tumor growth and is also expressed in activated
fibroblasts involved in tissue remodeling (O’Brien and O’Connor,
2008). Whether and how the inhibition of FAP may contribute
to the clinical effects of linagliptin is not known at present, but it
is of interest that linagliptin exerts a role in reparative processes
following wound injury.
PRE-CLINICAL STUDIES
PHARMACOKINETICS
Pharmacokinetics of linagliptin is characterized by its binding
to the DPP-4 target, not only in plasma, but mainly in tissues,
where the enzyme is bound to membranes (Greischel et al.,
2010). After single or repeated oral administration in male Fis-
cher rats, linagliptin is highly present in kidney, liver, and lung,
coincident with the distribution of DPP-4 (Fuchs et al., 2009b;
Retlich et al., 2009). Absorption of linagliptin is modified by
intestinal P-glycoprotein. In Wistar rats receiving a single oral
dose of linagliptin, administration of a P-glycoprotein inhibitor
produced an increased bioavailability of the drug (Fuchs et al.,
2009a), suggesting that P-glycoprotein activity limits absorption
of linagliptin.
Intravenous administration produces a non-linear increase in
linaglipin tissue concentrations with increasing doses, suggesting
the presence of saturable binding sites. These correspond with
peripheral DPP-4, either in plasma and tissues, as also suggested
by the fact that, in DPP-4-deficient rats, the amount of linagliptin
in tissues increases linearly with dose and is eliminated rapidly
whereas, in wild-type rats, increase in tissues is less dose pro-
portional and its peripheral decline is much slower compared to
DPP-4-deficient rats (Retlich et al., 2009). Following administra-
tion of a low-dose of linagliptin, AUC is significantly reduced and
terminal half-life is significantly shorter in DPP-4 deficient rats
compared to wild-type animals (Retlich et al., 2009). Hence, bind-
ing to DPP-4 in plasma and tissues potently affects linagliptin
pharmacokinetics leading to a non-linear profile, a long termi-
nal half-life, and a prolonged exposure to the drug. Based on these
observations, and as also confirmed in human studies, tissue accu-
mulation of linagliptin is unlikely and steady state conditions are
reached very quickly.
Metabolism does not primarily affect linagliptin that is rather
mainly eliminated unmodified. After repeated oral administration,
the great part of linagliptin is excreted through the intestinal tract,
a major part through the bile and a minor component (about 12%)
directly into the gut, independently of biliary excretion (Fuchs
et al., 2009b). In contrast only traces are found in urine (Fuchs
et al., 2009a,b). Furthermore, following a single oral administra-
tion, the majority of drug is eliminated within 24 h, although about
4% is still present after 96 h.
IN VIVO STUDIES IN ANIMAL MODELS
Administration of linagliptin to Han Wistar rats produces inhibi-
tion of DPP-4 in plasma that appears after 30 min, is maintained
7 h after treatment and is still present at 24 h. Maximal effects are
observed with doses of 3 and 10 mg/kg (90% inhibition), whereas
more than 70% inhibition is achieved following 1 mg/kg. Calcu-
lated ED50 values are 0.3 and 0.9 mg/kg, 7 and 24 h post-dose,
respectively (Thomas et al., 2008).
If inhibition of plasma DPP-4 activity is compared with
that achieved using the same dosage of other DPP-4 inhibitors,
linagliptin exhibits a similar efficacy vs. other compounds, at the
7 h time point. An exception is sitagliptin, that appears less effec-
tive at both time points examined, 7 and 24 h. In contrast, at 24 h,
linagliptin exhibits a sustained and maximal inhibition of DPP-4
activity, not observed with the other drugs (Thomas et al., 2008).
Similar to other DPP-4 inhibitors, linagliptin (1 mg/kg) reduces
blood glucose levels and suppresses glucose AUC between 0 and
120 min (about 50% reduction), when administered 45 min before
glucose challenge. In contrast to other compounds, linagliptin
maintains this effect (between 20 and 30% AUC reduction) when
administration of the drug precedes by 16 h glucose load (Thomas
et al., 2008).
In diabetic Zucker rats, administration of linagliptin 30 min or
24 h before an oral glucose tolerance test (OGTT) reduces blood
glucose peak levels and plasma glucose AUC. This effect is accom-
panied by increase in GLP-1 and insulin levels (Thomas et al.,
2008). In animals treated with linagliptin, while the increase of
GLP-1 levels precedes glucose load and is maintained thereafter,
insulin levels are not elevated in the fasting state, but sharply
increase after feeding.
In an established animal model of diabetes, obtained with
administration of a low-dose streptozotocin (STZ) and high-fat
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diet (HFD), the HFD/STZ rat exhibiting both hyperglycemia and
hyperinsulinemia, oral daily administration of linagliptin (1, 3,
10 mg/kg), for 4 weeks, produces a dose-dependent inhibition of
plasma DPP-4 (by 59, 78, and 87% with increasing doses) vs. levels
at time 0, when measurements are carried out at the end of the
study period (day 27), 21 h after last administration of the drug
(Thomas et al., 2009). Reduction of DPP-4 activity is paralleled
by decrease in blood glucose concentrations, glucose AUC, and
post-prandial glucose levels, the latter indicating improved glucose
tolerance (Thomas et al., 2009). An increase in active GLP-1 is also
observed following multiple, once daily dosing of linagliptin, with
no change of insulin levels. Furthermore, daily administration of
linagliptin causes a significant, dose-dependent decrease of HbA1c
with changes of 0.8, 0.9, and 1.0% at linagliptin doses of 1, 3, and
10 mg/kg, respectively.
Similar effects after chronic treatment with linagliptin are
observed in a more drastic model of diabetes, the Zucker diabetic
rat that exhibits marked insulin resistance, progressive beta-cell
failure with age and a severe evolution of the disease. In this ani-
mal model, linagliptin acutely reduces glucose concentrations after
OGTT and elevates GLP-1 levels, differently from vildagliptin, in a
sustained and long-lasting manner (Thomas et al., 2008) without
affecting basal insulin levels. In Zucker diabetic rat, chronic treat-
ment with linagliptin does not cause change in body weight, but
reduces cumulative food intake by 6%, in contrast to vildagliptin
that does not modify this parameter.
In NOD mice that spontaneously develop a form of insulin-
dependent diabetes caused by an autoimmune T cell-dependent
destruction of islets, thus resembling human type 1 diabetes,
linagliptin affects all the above described parameters. Specifically,
exposure to linagliptin, given with food at doses of 3–10 mg/kg for
8 weeks, delays the onset and reduces the incidence of diabetes; it
in fact induces reduction of basal blood glucose levels, decreases
water intake and enhances GLP-1 levels. In addition, it signifi-
cantly increases beta-cell mass in the pancreas without modifying
the non-beta-cell component (Jelsing et al., 2012).
Interestingly, recent evidence suggests a positive interaction of
linagliptin with an inhibitor of sodium-glucose co-transporter 2
(SGLT2) that is emerging as a novel target for treatment of T2DM.
In genetically diabetic mice, linagliptin improves in fact the effects
induced by the SGLT2 inhibitor, not only in terms of glycemic
control and islet function, but also with regards to the expression
of genes associated with the inflammatory response (Chen et al.,
2012).
ADDITIONAL EFFECTS OF LINAGLIPTIN IN ANIMALS MODELS
The effects of linagliptin are not restricted to direct control of
glycemic levels. As already mentioned, linagliptin in fact increases
beta-cell mass component in the pancreas (Jelsing et al., 2012).
In human cell islets in vitro, linagliptin (100 nM for 48 h) pro-
tects from apoptosis induced by exposure to insults such as
palmitic acid, interleukin-1/interferon-γ, or hydrogen peroxide
(Shah et al., 2010), restores beta-cell function and reverts oxidative
stress responsible for islet dysfunction.
When administered, in a period comprised from 4 weeks to
3 months (3 or 30 mg/kg), to diet-induced obese rats and HFD-fed
mice, linagliptin significantly reduces plasma leptin levels, as well
as hepatic steatosis, measured as hepatic red oil staining and/or by
magnetic resonance spectroscopy (Kern et al., 2012; Klein et al.,
2012). The latter effect is particularly relevant as liver fat content
correlates with metabolic disturbances, and signs of improved
hepatic steatosis, as those observed following linagliptin, can be
predictor of a better controlled glucose homeostasis. In addi-
tion, in these obese mice, high doses of linagliptin significantly
reduce inflammatory response in adipose tissue, as measured by
the number of infiltrating macrophages, and negatively affect the
expression of several genes related with fatty acid synthesis and oxi-
dation and primarily involved in inflammation (Kern et al., 2012).
It is highly plausible that all these effects on lipid metabolism
significantly contribute to the global improved insulin sensitivity
induced by linagliptin. In obese rats, however, linagliptin does not
modify total body weight, cumulative food intake or total body
fat (Klein et al., 2012), but interestingly, it reduces weight regain
following exenatide withdrawal (Vickers et al., 2012).
Linagliptin also seems to be endowed with vascular protec-
tive properties as it induces vasodilation in isolated aortic rings
under basal conditions, in a concentration-dependent manner.
This effect is mimicked by vildagliptin, but not by other DPP-
4 inhibitors. It also affects vascular dysfunction-related reactive
oxygen species and inflammation, thus exhibiting anti-oxidative
and anti-inflammatory properties (Kröller-Schön et al., 2012).
Of note, linagliptin exhibits a protective effect against diabetes-
dependent renal impairment. In diabetic endothelial nitric oxide
synthase (eNOS) knockout mice, an established model of diabetic
nephropathy, linagliptin, given as add-on therapy to the standard
treatment telmisartan, improves albuminuria, a predictor of dia-
betic nephropathy, and reduces plasmatic levels of osteopontin, a
marker of vascular calcification. These effects are accompanied by
reduction of glomerulosclerosis and renal oxidative stress, as mea-
sured by accumulation of malondialdehyde, as well as reduction
of tumor necrosis factor α (TNF-α) levels, a marker of systemic
inflammation (Alter et al., 2012).
Inhibition of DPP-4 has been reported to have beneficial effects
on protection from myocardial ischemic damage and ensuing
improvement of cardiac function. Among possible mechanisms of
action, a reduced degradation of myocardial SDF-1α, a substrate
for DPP-4, with subsequent increased recruitment of circulat-
ing CXCR-4+ stem cells that may favor tissue repair. Alterna-
tively, increased incretin acting at its receptor could activate path-
ways improving tissue repair. Treatment with linagliptin (given
once daily for 7 days, starting 2 days before ischemia/reperfusion)
induced less severe histological features of cardiac damage and
reduced infarct size and myocardial fibrosis after ischemia reper-
fusion in rats (Hocher et al., 2012b). A similar reduction of
infarct size is observed when linagliptin treatment is started
4 weeks before ischemia/reperfusion and is prolonged for 8 weeks
thereafter. Linagliptin treatment also increased the expression
of CD34, c-kit, CXCR-4, and SDF-1α, suggestive of enhanced
recruitment of CXCR-4+ circulating progenitor cells that may
be responsible for a better reparative process (Hocher et al.,
2012b).
In ob/ob mice, that are known to exhibit delayed and impaired
wound healing, treatment with linagliptin (3 mg/kg/day) while
reducing hyperglycemia, improves wound closure and wound
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morphology. However, even at very high doses (30 mg/kg/day),
it does not affect wound healing process in normoglycemic
mice. The effects observed in ob/ob mice are accompanied
by reduced influx and persistence of polymorphonuclear neu-
trophils, as well as infiltration of macrophages in wounds
(Schürmann et al., 2012). Such effects appear extremely impor-
tant and identify a potential additional effect of linagliptin.
Reduction of hyperglycemia in fact does not necessarily cor-
relate with improvement of wound healing. In addition, the
high expression of DPP-4 in the skin and its down-regulation
following injury suggest a role for the enzyme in reparative
processes. Interestingly enough, in ob/ob mice, DPP-4 expres-
sion in the skin is absent at early times following injury, but is
increased in the late phases of wound repair (Schürmann et al.,
2012).
Finally, very recent data have shown that treatment with
linagliptin produces a neuroprotective effect, independent of its
glucose lowering action. Specifically, in a model of stroke induced
by middle cerebral artery occlusion in normal and diabetic mice,
linagliptin is effective in reducing stroke volume (with a greater
effect in normal mice) and in increasing the number of viable
neurons in the peri-infarct area (Darsalia et al., 2012).
STUDIES IN HUMANS
PHARMACOKINETICS
First-human study was carried out to test pharmacodynamic
and pharmacokinetic features as well as safety and tolerability of
linagliptin (Hüttner et al., 2008). A single dose of oral linagliptin
ranging from 2.5 to 600 mg/day produced different t max values,
from 0.7 to 3 h, depending on the dose. The 5 mg dose resulted in
a Cmax of 5.71 nmol/L, t max of 1.47 h, t 1/2 of 69.7 h, and very
limited excretion in urine. In dose groups comprised between
5 and 50 mg, the terminal half-lives were approximately 70–80 h
(69.7–79.9) whereas they ranged from 128 to 184 h in dose groups
from 100 mg and above (Hüttner et al., 2008). Comparable phar-
macokinetic profiles were observed in type 2 diabetic patients
following single administration of linagliptin (2.5, 5, and 10 mg).
Linagliptin was rapidly absorbed with a t max of approximately
1.5 h. AUC and Cmax increased with dose, but, as already observed
in healthy subjects (Hüttner et al., 2008), the increase was less
than dose proportional. This is likely due to high-affinity sat-
urable binding of linagliptin to DPP-4. At low concentrations
(1 nmol/L), in fact, binding of linagliptin to plasma protein is
complete (99%) but it decreases to 70–80% at concentrations
higher than 100 nmol/L (Fuchs et al., 2012). At low plasma con-
centrations, linagliptin free fraction is thus very low whereas,
at higher plasma concentrations, linagliptin saturates DPP-4, its
free fraction increases and pharmacokinetic parameters, including
volume of distribution and clearance, are modified. As a con-
sequence, terminal half-life is long, ranging from 110 to 130 h,
depending on the dose administered. However, daily adminis-
tration induced only moderate accumulation and a steady state
level was yielded after 4–6 days following 1, 2.5, and 5 mg dose
(Heise et al., 2009). Linagliptin showed a low rate of hepatic
metabolism and renal excretion was minimal, being less than
1% on day 1 and between 3 and 6% on day 12 (Heise et al.,
2009).
Food intake does not modify linagliptin pharmacokinetics in
a clinically relevant manner. In fact, in subjects administered a
high-fat meal, AUC0–72 of linagliptin was similar to that of con-
trol subjects. Although t max was delayed by about 2 h (from 1.02 to
2.99 h) and Cmax was reduced by 15%, these changes did not affect
the overall exposure to the drug and did not modify its pharma-
codynamics (Graefe-Mody et al., 2011c). It can then be concluded
that linagliptin can be taken independent of meals as food does
not seem to have any clinically relevant effect on the efficacy of
the drug.
PHARMACODYNAMICS
Linagliptin induced marked inhibition of DPP-4 activity in both
healthy subjects (Hüttner et al., 2008) and type 2 diabetic patients
(Heise et al., 2009). According to Hüttner et al. (2008), a dose as
low as 2.5 mg linagliptin caused about 70% inhibition of DPP-4
activity, whereas almost complete inhibition was observed at doses
above 25 mg. The time needed to achieve maximum inhibition was
variable depending on the dose and was about 3 h with the lowest
doses. The inhibition was long-lasting and DPP-4 activity did not
return to baseline levels after 96 h. In diabetic patients, with the
5 mg dose, 92.3% DPP-4 inhibition was observed at steady state
and over 80% inhibition over a 24 h-interval after drug intake was
still present (Heise et al., 2009). This level of inhibition (>80%)
was maintained also after long-term treatments (12 and 24 weeks),
when mean linagliptin trough concentrations were constant over
time, at concentrations around 6.5 nmol/L (Del Prato et al., 2011).
When patients were subjected to OGTT, linagliptin significantly
reduced plasma glucose levels in a dose-dependent manner, start-
ing at the 2.5 mg dose. This effect was present at 26 h, but was more
pronounced at steady state,measured at 13 days (Heise et al., 2009).
PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH
HEPATIC OR RENAL IMPAIRMENT
In a phase I, parallel group-comparison study, 5 mg/day linagliptin
was administered for 7 days to healthy controls and subjects with
mild, moderate, and severe hepatic impairment. None of the
groups showed significant changes in linagliptin pharmacokinetic
parameters (AUC, Cmax, and t max), so that no dose adjustment is
required in these patients. In fact, about 80% DPP-4 inhibition was
present in all groups examined (Graefe-Mody et al., 2012). This
observation appears particularly relevant in view of the potential
correlation of type 2 diabetes with altered hepatic function and
mainly with respect to the predominant non-renal excretion of
linagliptin.
Pharmacokinetic profiles following linagliptin administration
were investigated, both after single dose and at steady state, in
patients with renal impairments of various degrees. Absorption
of linagliptin after single and multiple dosages was similar to that
observed in healthy and diabetic subjects, i.e., approximately or
less than 3 h to reach maximal plasma concentrations. In addi-
tion, plasma concentrations 24 h after a single dose were similar
in patients with mild, moderate, and severe renal impairment
and were not modified by the concomitant presence of type
2 diabetes. AUC and maximal plasma concentrations at steady
state were similar or only slightly increased in patients with
moderate renal impairment when compared to healthy controls.
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In addition accumulation t 1/2 of linagliptin following multiple
5 mg/day dose did not show any significant change in control and
diabetic subjects, regardless of renal function (Graefe-Mody et al.,
2011b).
Linagliptin present in urine was very low, around 1% in healthy
controls, and reached only 4% in patients with renal impairment.
Renal dysfunction did not modify linagliptin pharmacodynamics,
as about 80% inhibition of DPP-4 was present, irrespective of renal
function conditions.
These features make linagliptin unique among DPP-4
inhibitors as all other compounds are mainly excreted by the
kidney and exhibit modified kinetics under conditions of renal
impairment. After a single oral administration, approximately
87% of sitagliptin, 75% of saxagliptin, and 85% of vildagliptin
are excreted in urine. The three drugs show profound changes in
their plasma levels with increasing renal impairment, exhibiting
already a twofold increase when a moderate renal dysfunction is
present (Graefe-Mody et al., 2011b).
CLINICAL STUDIES
A detailed report of all the clinical studies that have been car-
ried out with linagliptin is beyond the scope of present review.
Linagliptin has in fact shown a clinical efficacy that is comparable
to that observed with other DPP-4 inhibitors. A summary of the
clinical trials with linagliptin is reported in Table 1.
CO-ADMINISTRATION OF LINAGLIPTIN WITH OTHER ANTI-DIABETIC
DRUGS
No reciprocal interaction was evident when linagliptin and met-
formin were administered together (Graefe-Mody et al., 2009).
Metformin per se did not modify DPP-4 activity and did not affect
inhibition of the enzyme induced by linagliptin in healthy subjects.
No clinically relevant pharmacokinetic interactions at steady state
between the two drugs were observed. Metformin increased AUC
by 20% and t max of linagliptin by about 50%, but these effects
are unlikely to have clinical relevance. Conversely, linagliptin co-
administration only slightly reduced metformin Cmax and delayed
its t max.
A randomized open-label, two-way crossover study exam-
ined the effects of co-administration of multiple oral doses
of linagliptin (5 mg/day× 6 days) and a single dose of gly-
buride (1.75 mg/day administered for 1 day) on the recipro-
cal pharmacokinetic parameters of the two drugs. Glyburide
did not affect any pharmacokinetic feature of linagliptin and
conversely, linagliptin slightly reduced glyburide AUC and
Cmax without achieving a clinically relevant effect (Graefe-
Mody et al., 2011d). As glyburide is a recognized substrate of
CYP2C9 and CYP3A4, this lack of interaction confirms that
linagliptin does not modify the activity of these metabolic
enzymes.
Linagliptin did not either affect pharmacokinetics of pioglita-
zone when the two drugs were administered together. This may
appear particularly significant since pioglitazone is a substrate
for CYP2C8. Hence, pioglitazone (45 mg/day) did not modify
linagliptin (10 mg/day) AUC and Cmax, whereas linagliptin only
slightly reduced pioglitazone Cmax (Graefe-Mody et al., 2010b).
The two drugs appear fully administrable in combination with no
relevant pharmacokinetic interaction.
INTERACTION OF LINAGLIPTIN WITH OTHER DRUGS NOT DIRECTLY
CORRELATED WITH DIABETES
An open-label, multiple-dose study examined, in healthy subjects,
the pharmacokinetic interaction of linagliptin (10 mg/day) and
simvastatin (40 mg/day), that is classified as a sensitive substrate
of CYP3A4. Changes in CYP3A4 activity may significantly modify
simvastatin metabolism, leading even to the occurrence of severe
adverse effects. Co-administration of linagliptin increased (by 10–
30%) both exposure and Cmax of simvastatin and its active analog
simvastatin acid (Graefe-Mody et al., 2010a), without however
achieving clinical relevance in terms not only of pharmacokinetic
parameters, but also of safety and appearance of adverse effects
during co-administration.
Eighteen healthy subjects were enrolled to evaluate the recip-
rocal pharmacokinetic interaction of linagliptin and warfarin, a
CYP2C9 substrate. No pharmacokinetic parameter of linagliptin,
S-warfarin, and R-warfarin was modified and co-administration
did not significantly change the coagulation parameters prothrom-
bin time (PT) and international normalized ratio (INR; Graefe-
Mody et al., 2011a). Together with the study in which linagliptin
was co-administered with glyburide (Graefe-Mody et al., 2011d),
this study supports the concept that linagliptin does not sig-
nificantly affect CYP2C9 activity and that substrates for this
enzyme, such as warfarin, can be administered in conjunction
with linagliptin without dose changing.
To test the interaction of linagliptin with drugs that act as sub-
strate for P-glycoprotein, an open-label cross over study enrolling
20 healthy subjects was carried out to evaluate co-administration
of linagliptin and digoxin (Friedrich et al., 2011b). In vitro studies
have in fact indicated linagliptin as a weak P-glycoprotein inhibitor
(Ishiguro et al., 2013). There was no significant change in digoxin
pharmacokinetics and all parameters were within the bioequiva-
lence range 80–125%, a critical aspect due to the low therapeutic
index of digoxin.
Due to the wide use of anti-diabetic drugs in women of fertile
age, the potential of impact of linagliptin on pharmacokinetics of
an oral contraceptive combination composed of ethinyl estradiol
(30µg) and levonorgestrel (150µg) was examined in an open-
label, multiple-dose study carried out in healthy women. None of
the parameters examined including both AUC and Cmax at steady
state were significantly affected by linagliptin co-administration,
with values within the standard acceptance limit of bioequivalence
80–125% (Friedrich et al., 2011a).
SAFETY AND TOLERABILITY
In a phase I study carried out by Hüttner et al. (2008), linagliptin
was shown to be well tolerated in healthy male volunteers when
administered in doses ranging from 2.5 to 600 mg per day. The
overall incidence of adverse effect was similar in placebo- and
linagliptin-treated subjects and there were no serious adverse
effects (Hüttner et al., 2008). Hypoglycemia was never present
and no changes of electrocardiographic or other cardiac function
parameters could be detected (Hüttner et al., 2008). In this respect,
a randomized, double-blind, placebo-controlled study was carried
out in healthy subjects to evaluate the potential effect of linagliptin
on QT interval. At the therapeutic dose (5 mg/day) and the 20-fold
therapeutic dose (100 mg/day) administered, linagliptin did not
cause any prolongation of the QT interval (Ring et al., 2011).
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Table 1 | Summary of major results obtained with linagliptin in clinical studies.
Treatment Adjusted mean (SE)
change from baseline
in HbA1c (%)
Adjusted mean (SE)
change from baseline
in FPG (mmo/l)
Achievement of
target HbA1c
<7% (% of patients)
Reference
4WEEKS OFTREATMENT
Linagliptin, 2.5 mg (n=26) −0.31* −16.6** – Forst et al. (2011)
Linagliptin, 5 mg (n=16) −0.37 −21.4 –
Linagliptin 10 mg (n=19) −0.28 −16.6 –
Placebo (n=16) – +3.2 –
24WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=336) −0.44 (±0.05) −0.5 (±0.1) 25.2 Del Prato et al. (2011)
Placebo (n=167) +0.25 (±0.07) +0.8 (±0.2) 11.6
18WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=151) −0.39 (±0.14) −0.7 (±0.3) 27.9 Barnett et al. (2012)
Placebo (n=76) +0.21 (±0.16) +0.4 (±0.3) 15.1
26WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=159) −0.13 (±0.7) −0.3 (±0.1) 30.2 Kawamori et al. (2012)
Linagliptin, 10 mg once daily (n=160) −0.19 (±0.7) −0.4 (±0.1) 34.4
Voglibose, 0.2 mg tid (n=162) +0.19 (±0.7) +0.1 (±0.1) 22.2
12WEEKS OFTREATMENT
Placebo (n=80) +0.63 (±0.08) +0.4 (±01) 10.0
12WEEKS OFTREATMENT
Linagliptin, 1 mg once daily (n=65) −0.15*** −0.36*** 15 Forst et al. (2010)
Linagliptin, 5 mg once daily (n=66) −0.48 −1.22 15
Linagliptin, 10 mg once daily (n=66) −0.42 −0.90 21
Glimepiride, 1 mg once daily (n=65) −0.90 – –
Placebo (n=71) +0.25 +0.7 1.4
(Add-on therapy to metformin)
24WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=524) −0.49 (±0.04) −0.6 (±0.1) 26 Taskinen et al. (2011)
Placebo (n=177) +0.15 (±0.06) +0.6 (±0.2) 9
(Add-on therapy to metformin)
24WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=142) −0.5 (±0.1) −0.5 (±0.2) – Haak et al. (2012)
Metformina, 500 mg bid (n=144) −0.6 (±0.1) −0.9 (±0.2) –
Metformina, 1000 mg bid (n=147) −1.1 (±0.1) −1.8 (±0.2) –
Linagliptin, 2.5 mg+metformina
500 mg bid (n=143)
−1.2 (±0.1) −1.8 (±0.2) –
Linagliptin, 2.5 mg+metformina
1000 mg bid (n=143)
−1.6 (±0.1) −2.7 (±0.2) –
Placebo (n=72) +0.1 (±0.1) +0.6 (±0.3) –
24WEEKS OFTREATMENT
Linagliptin, 5 mg+pioglitazone 30 mg
once daily (n=130)
−1.06 (±0.06) −1.8 (±0.1) 30.5 Gomis et al. (2011)
Placebo+pioglitazone, 30 mg once
daily (n=259)
−0.56 (±0.09) −1.0 (±0.2) 42.9
24WEEKS OFTREATMENT
Linagliptin, 5 mg once daily (n=793) −0.72 (±0.03) −0.3 (±0.1) 29.2 Owens et al. (2011)
Placebo (n=265) −0.10 (±0.5) +0.4 (±0.1) 8.1
(Add-on therapy to metformin and a
sulphonylurea)
SE, standard error; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose.
*Placebo-corrected mean change in HbA1c; **mg/dl; ***mean (+SE) change from baseline.
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However, with regards to general cardiovascular risk in patients
treated with linagliptin, a large meta-analysis evaluated cardiovas-
cular events observed in eight phase III studies using linagliptin
and different comparator anti-diabetic drugs (Johansen et al.,
2012). It can be concluded that a reduction of cardiovascu-
lar events is observed in patients with type 2 diabetes treated
with linagliptin vs. pooled comparators, suggesting a potential
cardiovascular benefit of linagliptin.
Safety and tolerability data obtained with linagliptin in eight
phase III clinical trials have been collected in a recent review arti-
cle and data obtained from about 3,500 patients were analyzed
altogether (Schernthaner et al., 2012). The overall incidence of
adverse events and serious adverse events was similar in placebo-
and linagliptin-treated patients (55 vs. 55.8 and 2.7 vs. 2.8%,
respectively).
Hypoglycemia was the most important adverse effect occur-
ring in 5.1% of patients receiving placebo vs. 8.2% of patients
on linagliptin treatment. Severe hypoglycemia was absent in
both groups. The higher incidence of hypoglycemia in linagliptin
group was most likely attributable to the concomitant treatment
with a sulfonylurea, as incidence of hypoglycemia was drastically
reduced when the sulfonylurea was not allowed (0.6 vs. 1% with
linagliptin and placebo, respectively). Among other adverse events,
the gastrointestinal disorders were more common, occurring in
10.5% of linagliptin-treated patients, very similar to placebo–
treated (11.4%). Diarrhea appeared in 2.1% of patients on either
linagliptin or placebo.
Other adverse events occurring at a frequency>2% were infec-
tions of the upper respiratory tract, urinary tract or nasopharyngi-
tis, headache, backpain, and hypertension. Minor adverse events,
including increase of hepatic enzyme and serum creatinine, blood,
and lymphatic disorders, occurred at an incidence <2% and
were similar in patients treated with linagliptin or placebo. Car-
diac disorders, mainly palpitation and tachycardia prevailed in
linagliptin-treated patients, but always at an incidence <0.5%
(Schernthaner et al., 2012).
An important issue that has been evaluated in several different
studies is weight gain, as it represents a main adverse event with
the use of other anti-diabetic drugs. DPP-4 inhibitors have gener-
ally a neutral effect on weight and, accordingly, the major part of
studies on linagliptin reports no significant change of body weight
or waist circumference at 12 or 24 weeks when the drug is admin-
istered alone (Hüttner et al., 2008; Del Prato, 2011; Del Prato et al.,
2011), or in combination with other anti-diabetic drugs (Owens
et al., 2011; Taskinen et al., 2011; Haak et al., 2012). Exceptions
were provided by studies carried out by Forst et al. (2010, 2011)
that reported a slight reduction in body weight after 4 or 12 weeks
of treatment with linagliptin in monotherapy (Forst et al., 2011)
or in addition to metformin (Forst et al., 2010). In contrast, an
increase in body weight was reported after 24 weeks of treatment
with linagliptin plus pioglitazone (2.3 kg) vs. pioglitazone plus
placebo (1.2 kg; Gomis et al., 2011).
CONCLUSION
Linagliptin is an oral, highly selective DPP-4 inhibitor causing
over 80% DPP-4 inhibition throughout the 24-h dosing inter-
val. It exhibits non-linear pharmacokinetic properties with a less
than dose proportional profile and is almost completely eliminated
via the enteric system, with less than 5% found in urine. This
particular feature makes linagliptin unique among other DPP-4
inhibitors, as no dosage adjustment is required in patients with
renal impairment and the drug can be used safely. The efficacy
of linagliptin in improving glycemic control and reducing HbA1
has been analyzed in several different studies with linagliptin used
in monotherapy or as add-on therapy to other commonly used
anti-diabetic drugs. Finally linagliptin has a good tolerability pro-
file, with the vast majority of adverse events of mild to moderate
severity.
Besides the pharmacokinetic and clinical features of linagliptin,
more impressively, preclinical studies have highlighted benefi-
cial effects on the cardiovascular system, and in skin reparative
processes that deserve further investigations.
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